JOSE-CARLOS (JC) GUTIÉRREZ-RAMOs
Dr. Gutiérrez-Ramos has over 20 years of drug discovery and development experience from leading global biopharmaceutical companies. He currently serves as Chief Executive Officer of Synlogic Inc. Previously, he served as Group Senior Vice President and global head of the BioTherapeutics Research at Pfizer where he was responsible for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. He also oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. Before that, Dr. Gutiérrez-Ramos was Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc.) into therapeutics. Prior to his work in the pharmaceutical industry, Dr. Gutiérrez-Ramos held senior leadership positions at several biotech companies, including Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc. He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery. During his academic career he was part of the Faculty at the Genetics Department of Harvard Medical School and the Basel Institute for Immunology in Switzerland. Dr. Gutiérrez-Ramos holds a Ph.D. in immunochemistry from the Autonoma University in Madrid, Spain.
Debasish Roychowdhury is an oncologist and a leader in the pharmaceutical industry. He is the President of Nirvan Consultants, LLC and serves in senior advisory roles for biotechnology companies, to help advance their pipeline of therapeutics. He is a member of the Board of Directors for Radius Pharma, Celyad Inc and Lytix Biopharma AS. He was one of the founding members of the Seragon Clinical and Scientific Advisory Board and has served as the Chief Medical Officer for Seragon and Ra Pharmaceuticals.
Debasish was the Senior Vice President of Global Oncology and Head of the Global Oncology Division at Sanofi from August 2009 to September 2013. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company.
Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences (MBBS, MD), Michael Reese Hospital (MD) and University of California, San Francisco (Fellowship).
ROBERTO D. POLAKIEWICZ
Dr. Polakiewicz has over 20 years of experience in the biotechnology industry while dedicating most of his career to establish Cell Signaling Technology, Inc. (CST) as a market leader in the research antibody field.
Dr. Polakiewicz is one of CST’s founding employees, and has been CST’s Chief Scientific Officer since 2005. During the past 16 years he has led Research and Technology development at the company and is responsible for the creation and implementation of four generations of novel antibody technologies and proteomics discovery platforms that have been critical to CST’s scientific and commercial success. Some of these platforms are now part of the Bluefin Biomedicine’s core technologies for target discovery.
Dr. Polakiewicz's research interests and experience span different fields including molecular and cell biology, signal transduction, and cancer. He holds a Ph.D. in Molecular Biology from the Hebrew University of Jerusalem in Israel and completed postdoctoral studies at the Whitehead Institute for Biomedical Research at M.I.T. Before joining CST Dr. Polakiewicz was a staff scientist at New England Biolabs, Inc.